Factor XIII is a blood protransglutaminase that is distributed in plasma and platelets. The extracellular and intracellular zymogenic forms differ in that the plasma zymogen contains A and B subunits, while the platelet zymogen has A subunits only. Both zymogens form the same enzyme. Erythrocytes, in contrast, contain a tissue transglutaminase that is distinct from Factor XIII. In this study other bone marrow-derived cells were examined for transglutaminase activity. Criteria that were used to differentiate Factor XIII proteins from erythrocyte transglutaminase included: (a) immunochemical and immunohistochemical identification with monospecific polyclonal and monoclonal antibodies to Factor XIII proteins, (b) requirement for thrombin cleavage to express activity, (c) pattern of fibrin cross-linking catalyzed by the enzyme, and (d) different electrophoretic mobilities in nondenaturing gel systems. By these criteria human peripheral blood monocytes, peritoneal macrophages, and monocytes maintained in culture contain an intracellular protransglutaminase that is the same as platelet Factor XIII. The monocyte-macrophage protein is thrombin-sensitive, and under appropriate conditions there is no enzyme expression without activation of the zymogen. Both the monocyte-macrophage zymogen and enzyme have the same electrophoretic mobilities as platelet Factor XIII zymogen and enzyme. Antibody to A protein reacts with the monocyte-macrophage protein. B protein is not associated with this intracellular zymogen. By immunoperoxidase staining monocyte-macrophage protein seems to be localized in the cytoplasm, similar to the known cytoplasmic distribution of platelet and megakaryocyte Factor XIII. These procedures were also used to study populations of human granulocytes and lymphocytes, and protransglutaminase activity was not observed in these cells.
Introduction
Transglutaminases constitute a class of widely dispersed, Ca2+-dependent enzymes that catalyze an acyl transfer reaction between the y-carboxamide group of a peptide-bound glutamine residue and various primary amines. Several distinct types of transglutaminases have been identified, of which the most well characterized are tissue transglutaminase and Factor XIIIa. A tissue transglutaminase, which may be present in many cell types, is usually isolated from liver or erythrocytes (1) . It is a monomeric protein (relative molecular weight [Mn' -75,000-80,000) which has only been detected as an active enzyme; no zymogen has been found (2) (3) (4) . Factor XIIIa, the blood coagulation enzyme that was first found to catalyze the covalent stabilization of fibrin, exists in two zymogenic forms. Extracellular or plasma Factor XIII is a noncovalently associated tetramer (MW-320,000), consisting of two A and two B subunits; intracellular Factor XIII is a dimer (Mr -150,000) of A subunits. The A chains in both zymogens are identical (Mr -75,000) (5) . With activation, both zymogens give rise to the same enzymatic activity. Intracellular Factor XIII has been identified in platelets, megakaryocytes, placenta, and uterus (6, 7) .
Transglutaminase activity can be monitored by the covalent incorporation of a suitable primary amine, usually a lysine analogue such as dansylcadaverine or putrescine, into a peptidebound acceptor glutamine residue (8, 9) . Factor XIIIa activity can be differentiated from tissue transglutaminase by the requirement for activation of the Factor XIII zymogen to expose the active center cysteine. This is usually achieved by thrombin cleavage of the A protein in the presence of calcium ions (10) . Other in vitro mechanisms for zymogen activation include high concentration of calcium alone or calcium plus thiocyanate (1 1-13). Tissue transglutaminase is immunochemically distinct from platelet and plasma Factor XIII. The tissue protein and the Factor XIII proteins also have different electrophoretic mobilities in nondenaturing gel systems (14, 15) .
Using an assay based on the incorporation of ['4C]putrescine into NN'-dimethylcasein, Novogrodsky et al. (16) identified transglutaminase activity in human peripheral blood lymphocytes and macrophages and also found that enzyme activity in lymphocytes, but not in macrophages, was enhanced by prior incubation of the cells with high concentrations of concanavalin A and phytohemagglutinin. Schroff et al. (17) used fluorescent staining of cells with dansylcadaverine and incorporation of ['4C ]putrescine into a-casein by cell homogenates to detect transglutaminase activity in murine macrophages. In this study monocytes were negative and so also were lymphocytes, with or without concanavalin A stimulation. Transglutaminase activity has also been detected in murine leukemia Ml cells during the course of differentiation into mature, macrophagelike Ml+ cells (18 Protein concentration of cell extracts was determined with the protein assay from Bio-Rad Laboratories, Richmond, CA, with bovine albumin as the standard. Samples containing Triton X-100 were corrected for the presence of detergent.
Activity measurement. Factor XIII activity was quantitated by incorporating monodansylcadaverine (Sigma Chemical Co., St. Louis, MO) into casein (8) . The complete assay system included preincubation of test material with thrombin and CaCl2 to activate the zymogen. Test samples were also assayed without thrombin and CaCl2 activation and with thrombin alone and CaCI2 alone. In all cases CaCl2 was present in the incorporation phase. Pooled normal, platelet-poor plasma and preparations of purified plasma Factor XIII (24) and platelet Factor XIII (25) were used as controls for all studies. This assay can detect -10-15 ng of A protein activity.
Assessment of electrophoretic mobility, based on activity detection, was made by activity staining of the gel, after electrophoresis under nondenaturing conditions (14) . Agarose gel electrophoresis was performed at 10'C at 18-20 V/cm in 1-mm thick gels containing 0.8% agarose (Seakem, Springfield, NJ), on GelBond NF supports. Samples were subjected to electrophoresis in 0.1 M Barbital I (Bio-Rad Laboratories), pH 8.6, containing 2 mM EDTA. Factor XIII activity was visualized by staining the electropherograms at 370C for 90 min with a solution containing 10 IU/ml bovine thrombin (Parke-Davis), 35 mM CaC12, 2 mM dithiothreitol, 0.7 mM monodansylthiacadaverine (Larodan Fine Chemicals, Malmo, Sweden), and 1.0% casein Hammarsten (ICN K & K Laboratories, Inc., Plainview, NY) in 50 mM Tris-HCI, pH 7.5. In some experiments thrombin or CaCl2 was omitted from the staining solution. Purified plasma and platelet Factor XIII and erythrocyte transglutaminase were used as electrophoretic mobility markers for the various types of transglutaminases. After incubation in the staining solution, gels were immersed in 10% trichloroacetic acid for 20 min, washed repeatedly in 10% acetic acid, and then neutralized in 50 mM Tris-HCl, pH 7.5. Fluorescent bands were readily visualized in ultraviolet light, and they were photographed through a Wratten No. 15 filter. This procedure can detect <0.9 nM Factor XIII activity.
Immunochemical characterization. Both monoclonal and polyclonal antibodies to Factor XIII proteins were used. Monoclonal antibodies were prepared by immunizing with purified preparations of A and B proteins. Positive clones were subcloned in soft agar two or three times (26). Monoclonal antibodies were characterized with respect to immunoglobulin class, ability to bind the various molecular forms of Factor XIII proteins, and ability to inhibit Factor XIII activation or activity. Monoclonal antibodies to A protein and to B protein were used for immunoblotting (27, 28) , after electrophoresis of samples in 6% sodium dodecyl sulfate (SDS) polyacrylamide gels (29).
Monospecific rabbit antisera were used to detect Factor XIII in all extracts by crossed immunoelectrophoresis (30) . It had previously been determined that anti-A reacted only with A and not B, and anti-B reacted only with B and not A (31, 32 
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-W I ; . (38) . Tissue transglutaminase will also cross-link fibrin, but the cross-linking pattern shows high molecular weight polymers of a-chains and y-chains and no y-chain dimer formation (7).
When Factor XIII-deficient plasma or Factor XIII-free fibrinogen was clotted with the macrophage soluble fraction, and the clot was solubilized and examined by reduced SDS gel electrophoresis, the fibrin cross-linking pattern showed 'ydimer and a-polymer formation (Fig. 6 ). y-dimer formation differentiates Factor XIIIa activity from tissue transglutaminase, since y-dimers are not observed with the tissue enzyme (7) .
The possibility that monocytes-macrophages absorbed A chain from plasma or serum is unlikely. Plasma A chain forms a tight noncovalent complex with B chain; and there is no evidence for free, uncomplexed A chain in plasma, either in the precursor or active enzyme forms. We have also not been able to find free B chain in plasma (32) . It seems improbable, therefore, that monocytes selectively absorb A chain, leaving B chain behind in plasma. Serum contains a small amount of A chain, which is all in the active enzyme form (32) . Hence, this is not the source of A chain for the monocytes in culture. In addition, cells cultured in serum-free medium also contain protransglutaminase.
Additional support for the identification of A protein in monocytes is also provided by our recent studies with the human monocyte-macrophage cell line, U937. These cells stain with antibodies to A protein but not B protein, and the cell cytosol contains a protransglutaminase which is thrombin sensitive. When the cells are maintained in culture for 48 h in serum-free medium, no protransglutaminase activity can be detected in the cytosol without thrombin activation (39 In this study transglutaminase activity was not observed in granulocytes. By activity staining lymphocytes were also essentially negative. Very low activity was occasionally observed, which may have been due to the presence of some monocytes in the lymphocyte preparations. We have not been able to demonstrate the presence of A protein in unstimulated lymphocytes.
A specific function for monocyte-macrophage transglutaminase has not yet been determined. One possibility that has received attention involves receptor-mediated phagocytosis (41) . a2-macroglobulin is known to be a substrate for plasma Factor XIIIa (42, 43) , and macrophages bind a2-macroglobulin-protease complexes (44) . Evidence has been presented that ligandreceptor binding and internalization of a2-macroglobulin complexes require transglutaminase activity and that inhibitors of Factor XIII block both transglutaminase and endocytosis (45) . However, other investigators think that there are no direct data to support a role for transglutaminases in this process (46) . Transglutaminase could be active in other macrophage functions. It could, for example, be a source of readily activatable Factor XIII at inflammatory sites for the cross-linking of numerous substrate proteins, including collagen, fibronectin, and fibrinogen-fibrin. Monocytes-macrophages produce other coagulation factors (47-49), and these cells can also function in a manner similar to platelets to provide the membrane surface on which the prothrombinase complex assembles for the generation of thrombin (50) . Macrophages can also release fibrinolytic enzymes (51) . It is therefore becoming clear that macrophages may constitute an important cellular element in the regulation of hemostasis. Several reactions involved in fibrin formation and degradation require transglutaminasecatalyzed covalent cross-linking. The availability of a macrophage source of Factor XIII in the local microenvironment of clot formation requires further study to determine what role it might have in these reactions.
